$3.63
-0.05 (-1.36%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SANA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 11 tracked-famous managers (MARSHALL WACE, LLP, RENAISSANCE TECHNOLOGIES LLC, AQR CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, +6 more) · FINRA short interest 16.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)NCT06294236Evaluate safety and tolerability of SC291Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Biological: SC291 | Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis | 7 | Dec 2027 | ≤ 499 d | 2025-11-25 |
| Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)NCT06285422Evaluate safety and tolerability of SC262Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: SC262 | Non Hodgkin's Lymphoma, Large B-cell Lymphoma | 6 | Dec 2025 | — | 2025-11-28 |
| Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)NCT05878184Evaluate safety and tolerability of SC291Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: SC291 | Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | 16 | 2025-11-04 | — | 2025-10-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19